Twist Bioscience Financials

TWST Stock  USD 40.81  0.39  0.95%   
Based on the measurements of operating efficiency obtained from Twist Bioscience's historical financial statements, Twist Bioscience Corp is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At this time, Twist Bioscience's Short Term Debt is comparatively stable compared to the past year. Intangible Assets is likely to gain to about 18.4 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 49 M in 2025. Key indicators impacting Twist Bioscience's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio7.285.62
Significantly Up
Pretty Stable
The essential information of the day-to-day investment outlook for Twist Bioscience includes many different criteria found on its balance sheet. An individual investor should monitor Twist Bioscience's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Twist Bioscience.

Net Income

(197.25 Million)

  

Twist Bioscience Corp Earnings Geography

Please note, the imprecision that can be found in Twist Bioscience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Twist Bioscience Corp. Check Twist Bioscience's Beneish M Score to see the likelihood of Twist Bioscience's management manipulating its earnings.

Twist Bioscience Stock Summary

Twist Bioscience competes with Personalis, Natera, Guardant Health, Castle Biosciences, and IQVIA Holdings. Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company was incorporated in 2013 and is headquartered in South San Francisco, California. Twist Bioscience operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 989 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS90184D1000
CUSIP90184D100
LocationCalifornia; U.S.A
Business Address681 Gateway Boulevard,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.twistbioscience.com
Phone800 719 0671
CurrencyUSD - US Dollar

Twist Bioscience Key Financial Ratios

Twist Bioscience Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets702.1M961.4M776.4M614.3M706.5M478.9M
Other Current Liab27.7M53.5M40.0M34.9M40.1M21.9M
Other Liab158K351K5.1M60K69K65.6K
Net Tangible Assets150.4M334.8M540.1M789.4M907.8M953.2M
Net Debt(402.9M)(283.8M)(192.4M)(141.3M)(127.2M)(133.5M)
Retained Earnings(610.6M)(828.4M)(1.0B)(1.2B)(1.1B)(1.1B)
Accounts Payable14.9M20.1M14.1M1.6M1.9M1.8M
Cash465.8M378.7M286.5M226.3M260.3M200.2M
Other Assets4.4M3.4M49.9M(1K)(1.2K)(1.1K)
Net Receivables28.5M40.3M44.1M34.9M40.1M23.8M
Capital Surpluse470.4M794.6M1.2B1.6B1.9B2.0B
Inventory31.8M39.3M32.1M24.1M27.7M19.1M
Other Current Assets16.6M11.9M11.7M11.4M13.1M8.9M
Total Liab121.3M172.0M153.0M141.6M127.5M122.2M
Total Current Assets546.5M596.5M424.3M346.8M398.8M321.6M
Short Term Debt18.0M13.6M14.9M29.6M34.1M35.8M
Intangible Assets18.3M59.7M54.5M14.5M16.6M18.4M
Net Invested Capital1.6M789.4M623.4M472.7M543.6M284.9M

Twist Bioscience Key Income Statement Accounts

The reason investors look at the income statement is to determine what Twist Bioscience's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
202020212022202320242025 (projected)
Tax Provision(1.9M)(10.4M)1.2M560K504K529.2K
Net Interest Income68K3.0M14.4M15.3M17.6M18.5M
Interest Income435K3.1M14.4M15.3M17.6M18.5M
Interest Expense367K80K5K29K26.1K24.8K
Total Revenue132.3M203.6M245.1M313.0M359.9M377.9M
Gross Profit51.7M84.2M89.7M133.3M153.4M161.0M
Operating Income(153.3M)(249.0M)(217.2M)(220.8M)(198.7M)(208.7M)
Ebit(155.9M)(249.0M)(203.5M)(208.1M)(187.3M)(196.7M)
Research Development69.1M120.3M106.9M90.9M104.5M64.0M
Ebitda(143.9M)(247.0M)(174.2M)(176.7M)(159.0M)(167.0M)
Cost Of Revenue80.6M119.3M155.4M179.6M206.6M216.9M
Income Before Tax(154.0M)(228.3M)(203.5M)(208.2M)(187.3M)(196.7M)
Net Income(152.1M)(217.9M)(204.6M)(208.7M)(187.9M)(197.2M)
Income Tax Expense(1.9M)(10.4M)1.2M560K504K529.2K

Twist Bioscience Key Cash Accounts

202020212022202320242025 (projected)
Change To Inventory(19.5M)(7.5M)7.2M8.0M9.2M9.6M
Investments183.7M(117.2M)50.6M(3.1M)(3.5M)(3.7M)
Change In Cash373.1M(87.1M)(91.0M)(60.1M)(54.1M)(51.4M)
Free Cash Flow(139.3M)(226.2M)(170.3M)(69.2M)(62.3M)(65.4M)
Depreciation9.8M16.5M29.3M31.4M36.1M38.0M
Other Non Cash Items1.9M2.7M4.0M46.9M53.9M56.6M
Capital Expenditures27.1M101.9M27.8M5.1M5.8M5.5M
Net Income(152.1M)(217.9M)(204.6M)(208.7M)(187.9M)(197.2M)
End Period Cash Flow467.4M380.3M289.3M229.1M263.5M201.5M
Change To Netincome11.6M17.2M37.1M82.3M94.7M99.4M

Twist Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Twist Bioscience's current stock value. Our valuation model uses many indicators to compare Twist Bioscience value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Twist Bioscience competition to find correlations between indicators driving Twist Bioscience's intrinsic value. More Info.
Twist Bioscience Corp is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Twist Bioscience's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Twist Bioscience by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Twist Bioscience Corp Systematic Risk

Twist Bioscience's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Twist Bioscience volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Twist Bioscience Corp correlated with the market. If Beta is less than 0 Twist Bioscience generally moves in the opposite direction as compared to the market. If Twist Bioscience Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Twist Bioscience Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Twist Bioscience is generally in the same direction as the market. If Beta > 1 Twist Bioscience moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Twist Bioscience Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Twist Bioscience's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Twist Bioscience growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.63

At this time, Twist Bioscience's Price Earnings To Growth Ratio is comparatively stable compared to the past year.

Twist Bioscience February 26, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Twist Bioscience help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Twist Bioscience Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Twist Bioscience Corp based on widely used predictive technical indicators. In general, we focus on analyzing Twist Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Twist Bioscience's daily price indicators and compare them against related drivers.

Additional Tools for Twist Stock Analysis

When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.